

# Maria Nachury

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2195335/publications.pdf>

Version: 2024-02-01

53  
papers

4,613  
citations

236833

25  
h-index

175177

52  
g-index

56  
all docs

56  
docs citations

56  
times ranked

5379  
citing authors

#	ARTICLE	IF	CITATIONS
1	Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. <i>Lancet, The</i> , 2016, 388, 1281-1290.	6.3	771
2	Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. <i>Lancet, The</i> , 2012, 380, 1909-1915.	6.3	517
3	Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2018, 154, 1334-1342.e4.	0.6	331
4	Safety and Efficacy of Antigen-Specific Regulatory T-Cell Therapy for Patients With Refractory Crohn's Disease. <i>Gastroenterology</i> , 2012, 143, 1207-1217.e2.	0.6	323
5	Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 395-401.	0.6	274
6	Development of the LÃ©mann Index to Assess Digestive Tract Damage in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2015, 148, 52-63.e3.	0.6	257
7	Early Administration of Azathioprine vs Conventional Management of Crohn's Disease: A Randomized Controlled Trial. <i>Gastroenterology</i> , 2013, 145, 758-765.e2.	0.6	242
8	Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study. <i>Gut</i> , 2018, 67, 53-60.	6.1	203
9	Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1593-1601.e2.	2.4	168
10	Comparative Acceptability and Perceived Clinical Utility of Monitoring Tools. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1425-1433.	0.9	149
11	Postoperative Complications after Ileocecal Resection in Crohn's Disease: A Prospective Study From the REMIND Group. <i>American Journal of Gastroenterology</i> , 2017, 112, 337-345.	0.2	138
12	One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 310-321.	1.9	128
13	Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2016, 150, 380-388.e4.	0.6	114
14	Fistula Plug in Fistulising Ano-Perineal Crohn's Disease: a Randomised Controlled Trial. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 141-148.	0.6	92
15	Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 485-493.	1.9	91
16	Outcomes 7 Years After Infliximab Withdrawal for Patients With Crohn's Disease in Sustained Remission. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 234-243.e2.	2.4	71
17	Efficacy and Safety of Induction Therapy With Calcineurin Inhibitors in Combination With Vedolizumab in Patients With Refractory Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 494-501.	2.4	62
18	Immunogenicity and Safety of Influenza Vaccine in Inflammatory Bowel Disease Patients Treated or not with Immunomodulators and/or Biologics: A Two-year Prospective Study. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 1096-1107.	0.6	43

#	ARTICLE	IF	CITATIONS
19	Vedolizumab for perianal Crohn's disease: a multicentre cohort study in 151 patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 719-727.	1.9	39
20	Oral Curcumin No More Effective Than Placebo in Preventing Recurrence of Crohn's Disease After Surgery in a Randomized Controlled Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1553-1560.e1.	2.4	35
21	Ileal or Anastomotic Location of Lesions Does Not Impact Rate of Postoperative Recurrence in Crohn's Disease Patients Classified I2 on the Rutgeerts Score. <i>Digestive Diseases and Sciences</i> , 2016, 61, 2986-2992.	1.1	34
22	Risk of Rectal Neoplasia after Colectomy and Ileorectal Anastomosis for Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 930-935.	0.6	34
23	Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium. <i>PLoS Medicine</i> , 2020, 17, e1003348.	3.9	31
24	Endoscopic Detection of Small Bowel Dysplasia and Adenocarcinoma in Crohn's Disease: A Prospective Cohort-Study in High-Risk Patients. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 47-52.	0.6	27
25	Acute hepatitis E: A cause of lymphocytic destructive cholangitis. <i>Human Pathology</i> , 2005, 36, 436-438.	1.1	26
26	Tofacitinib as salvage therapy for 55 patients hospitalised with refractory severe ulcerative colitis: A GETAID cohort. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 312-319.	1.9	26
27	Risk of Incident Cancer in Inflammatory Bowel Disease Patients Starting Anti-TNF Therapy While Having Recent Malignancy. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 1362-1369.	0.9	24
28	Ulcerative proctitis is a frequent location of paediatric-onset UC and not a minor disease: a population-based study. <i>Gut</i> , 2017, 66, 1912-1917.	6.1	24
29	Effectiveness and safety of anti-TNF therapy for inflammatory bowel disease in liver transplant recipients for primary sclerosing cholangitis: A nationwide case series. <i>Digestive and Liver Disease</i> , 2018, 50, 668-674.	0.4	24
30	Efficacy and safety of golimumab in Crohn's disease: a French national retrospective study. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 1077-1084.	1.9	23
31	Patients with Crohn's Disease with High Body Mass Index Present More Frequent and Rapid Loss of Response to Infliximab. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1853-1859.	0.9	23
32	Oral vancomycin induces sustained deep remission in adult patients with ulcerative colitis and primary sclerosing cholangitis. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 1247-1252.	0.8	23
33	Role of adherent and invasive <i>Escherichia coli</i> in Crohn's disease: lessons from the postoperative recurrence model. <i>Gut</i> , 2023, 72, 39-48.	6.1	22
34	Bowel damage and disability in Crohn's disease: a prospective study in a tertiary referral centre of the LÃ©mann Index and Inflammatory Bowel Disease Disability Index. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 889-898.	1.9	21
35	Extra-intestinal Manifestations at Diagnosis in Paediatric- and Elderly-onset Ulcerative Colitis are Associated With a More Severe Disease Outcome: A Population-based Study. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1326-1334.	0.6	19
36	INSPECT: A Retrospective Study to Evaluate Long-term Effectiveness and Safety of Darvadstrocel in Patients With Perianal Fistulizing Crohn's Disease Treated in the ADMIRE-CD Trial. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1737-1745.	0.9	19

#	ARTICLE	IF	CITATIONS
37	Radiological Response Is Associated with Better Outcomes and Should Be Considered a Therapeutic Target in Crohn's Disease. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2664-2674.	1.1	18
38	Previous Exposure to Multiple Anti-TNF Is Associated with Decreased Efficiency in Preventing Postoperative Crohn's Disease Recurrence. <i>Journal of Crohn's and Colitis</i> , 2016, 11, jw151.	0.6	17
39	Adalimumab dose escalation is effective and well tolerated in Crohn's disease patients with secondary loss of response to adalimumab. <i>Digestive and Liver Disease</i> , 2017, 49, 163-169.	0.4	15
40	Comparative Acceptability of Therapeutic Maintenance Regimens in Patients With Inflammatory Bowel Disease: Results From the Nationwide ACCEPT2 Study. <i>Inflammatory Bowel Diseases</i> , 2023, 29, 579-588.	0.9	13
41	Postoperative complications in elderly onset inflammatory bowel disease: a population-based study. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1652-1660.	1.9	12
42	Efficacy and Safety of Tumor Necrosis Factor Antagonists in Treatment of Internal Fistulizing Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 628-636.	2.4	12
43	Maintenance of Remission Among Patients With Inflammatory Bowel Disease After Vedolizumab Discontinuation: A Multicentre Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 896-903.	0.6	12
44	Impact of HIV Infection on the Course of Inflammatory Bowel Disease and Drug Safety Profile: A Multicenter GETAID Study. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 787-797.e2.	2.4	11
45	Faster and less invasive tools to identify patients with ileal colonization by adherent-invasive <i>E. coli</i> in Crohn's disease. <i>United European Gastroenterology Journal</i> , 2021, 9, 1007-1018.	1.6	11
46	Steroid-Free Deep Remission at One Year Does Not Prevent Crohn's Disease Progression: Long-Term Data From the TAILORIX Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2074-2082.	2.4	11
47	Efficacy of sacral nerve stimulation for poor functional results of J-pouch ileoanal anastomosis. <i>Techniques in Coloproctology</i> , 2014, 18, 355-360.	0.8	10
48	Comparative real-world effectiveness of vedolizumab and ustekinumab for patients with ulcerative colitis: a GETAID multicentre cohort study. <i>Scandinavian Journal of Gastroenterology</i> , 2022, 57, 1454-1462.	0.6	8
49	287 Efficacy of Adalimumab in Patients With Crohn's Disease and Symptomatic Small Bowel Stricture: A Multicentre, Prospective, Observational Cohort Study (CREOLE). <i>Gastroenterology</i> , 2015, 148, S-62.	0.6	6
50	Endoscopic balloon dilation of colorectal strictures complicating Crohn's disease: a multicenter study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 45, 101561.	0.7	4
51	Measuring patients' satisfaction with their anti-TNF treatment in severe Crohn's disease: scoring and psychometric validation of the Satisfaction for Patients in Crohn's Disease Questionnaire (SPACE-Q). <i>Patient Preference and Adherence</i> , 2014, 8, 1671.	0.8	3
52	Motivation to pursue anti-TNF treatment in patients with Crohn's disease – the SPACE motivation study. <i>Digestive and Liver Disease</i> , 2020, 52, 995-1001.	0.4	0
53	Prevalence of anti-TNF contraindications in Crohn's disease: A cross-sectional survey from the GETAID. <i>Digestive and Liver Disease</i> , 2022, 54, 1350-1357.	0.4	0